This protocol is judged by an institutional evaluation board, an independent group that critiques any clinical trials involving individuals. If a review requires a Schedule I drug, once the board approves the protocol as moral, the scientists must submit an application for an investigational new drug (IND) range with the FDA.“It’s imperative t